These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32367440)

  • 1. Immune suppression caused by PD-L2 expression on tumor cells in gastric cancer.
    Nakayama Y; Mimura K; Kua LF; Okayama H; Min AKT; Saito K; Hanayama H; Watanabe Y; Saito M; Momma T; Saze Z; Ohki S; Suzuki Y; Ichikawa D; Yong WP; Kono K
    Gastric Cancer; 2020 Nov; 23(6):961-973. PubMed ID: 32367440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival.
    Liu J; Li H; Sun L; Yuan Y; Xing C
    Biomed Res Int; 2020; 2020():2496582. PubMed ID: 32596285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity.
    Tanegashima T; Togashi Y; Azuma K; Kawahara A; Ideguchi K; Sugiyama D; Kinoshita F; Akiba J; Kashiwagi E; Takeuchi A; Irie T; Tatsugami K; Hoshino T; Eto M; Nishikawa H
    Clin Cancer Res; 2019 Aug; 25(15):4808-4819. PubMed ID: 31076547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ANO9 regulates PD-L2 expression and binding ability to PD-1 in gastric cancer.
    Katsurahara K; Shiozaki A; Kosuga T; Shimizu H; Kudou M; Arita T; Konishi H; Komatsu S; Kubota T; Fujiwara H; Okamoto K; Kishimoto M; Konishi E; Otsuji E
    Cancer Sci; 2021 Mar; 112(3):1026-1037. PubMed ID: 33404124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer-T cell coculture models.
    Mimura K; Kua LF; Xiao JF; Asuncion BR; Nakayama Y; Syn N; Fazreen Z; Soong R; Kono K; Yong WP
    Gastric Cancer; 2021 May; 24(3):611-623. PubMed ID: 33611641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.
    Yearley JH; Gibson C; Yu N; Moon C; Murphy E; Juco J; Lunceford J; Cheng J; Chow LQM; Seiwert TY; Handa M; Tomassini JE; McClanahan T
    Clin Cancer Res; 2017 Jun; 23(12):3158-3167. PubMed ID: 28619999
    [No Abstract]   [Full Text] [Related]  

  • 7. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
    Larsen TV; Hussmann D; Nielsen AL
    Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer.
    Wu Y; Zhao T; Jia Z; Cao D; Cao X; Pan Y; Zhao D; Zhang B; Jiang J
    J Gastroenterol Hepatol; 2019 Jul; 34(7):1201-1207. PubMed ID: 30353572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
    Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
    World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weitiao No. 3 (3) enhances the efficacy of anti-programmed cell death protein-1 immunotherapy by modulating the intestinal microbiota in an orthotopic model of gastric cancer mice.
    Xiaona H; Yuzhen LI; Chenyang Z; Hengzhou Z; Chenyu J; Xiaodan Z; Chencen Z; Chunhui J
    J Tradit Chin Med; 2024 Oct; 44(5):906-915. PubMed ID: 39380221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastric cancer mesenchymal stem cells regulate PD-L1-CTCF enhancing cancer stem cell-like properties and tumorigenesis.
    Sun L; Huang C; Zhu M; Guo S; Gao Q; Wang Q; Chen B; Li R; Zhao Y; Wang M; Chen Z; Shen B; Zhu W
    Theranostics; 2020; 10(26):11950-11962. PubMed ID: 33204322
    [No Abstract]   [Full Text] [Related]  

  • 12. Overexpression of DAPK1-mediated inhibition of IKKβ/CSN5/PD-L1 axis enhances natural killer cell killing ability and inhibits tumor immune evasion in gastric cancer.
    Guo Z; Zhou C; Zhou L; Wang Z; Zhu X; Mu X
    Cell Immunol; 2022 Feb; 372():104469. PubMed ID: 35114597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules.
    Zhang Y; Chen X; Mo S; Ma H; Lu Z; Yu S; Chen J
    J Pathol Clin Res; 2022 May; 8(3):257-267. PubMed ID: 35037417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry.
    Shinchi Y; Komohara Y; Yonemitsu K; Sato K; Ohnishi K; Saito Y; Fujiwara Y; Mori T; Shiraishi K; Ikeda K; Suzuki M
    Cancer Sci; 2019 Sep; 110(9):2711-2721. PubMed ID: 31294893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance and prognostic significance of PD-1/PD-Ls in non-metastatic bladder cancer: A role for PD-L2.
    Ariafar A; Ghaedi M; Rezaeifard S; Shahriari S; Zeighami S; Ghaderi A; Faghih Z
    Mol Immunol; 2020 Aug; 124():35-41. PubMed ID: 32512320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype.
    Takada K; Toyokawa G; Kinoshita F; Jogo T; Kohashi K; Wakasu S; Ono Y; Tanaka K; Oba T; Osoegawa A; Tagawa T; Azuma K; Okamoto I; Shimokawa M; Oda Y; Mori M
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2639-2650. PubMed ID: 32405745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological, immune and molecular correlates of
    Lingohr P; Dohmen J; Semaan A; Branchi V; Dietrich J; Bootz F; Kalff JC; Matthaei H; Dietrich D
    Epigenomics; 2019 May; 11(6):639-653. PubMed ID: 30821175
    [No Abstract]   [Full Text] [Related]  

  • 18. PD-L1 and PD-L2 expression in colorectal cancer.
    Zeynep O; Funda C; Evrim Y; Deniz A; Bülent Y; Fatih YN
    Indian J Pathol Microbiol; 2023; 66(1):31-37. PubMed ID: 36656207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for Esophageal and Gastric Cancer.
    Kelly RJ
    Am Soc Clin Oncol Educ Book; 2017; 37():292-300. PubMed ID: 28561677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].
    Wen SL; Li F; Zhao F; Zuo JJ; Deng YQ; Zhang W; Tao ZZ
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Apr; 55(4):384-390. PubMed ID: 32306637
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.